100% Shariah Compliant

The "Elite 7" Master Dashboard

An ultra-concentrated compounding engine built for the DSE market recovery. Continuous tracking, dynamic DCA execution, and strict value screening.

Market Data Link

ACTIVE

Connected to Hono Backend API

Investment Principles

Buy Quality, Not Hype: Focus on monopolies and duopolies with pricing power.
Screen Twice: Must pass Shariah compliance AND rigorous fundamental health checks.
Strict Valuation: Never overpay. Only accumulate when current P/E is below historical target P/E.
Automated DCA: Invest mechanically every month, ignoring short-term news sentiment.

Pharmaceuticals (Anchor)45%

SQURPHARMA (20%), RENATA (15%), ACMELAB (10%)

Industrials & Building Materials30%

LHBL (15%), BERGERPBL (15%)

FMCG & Consumer Staples25%

MARICO (15%), OLYMPIC (10%)

The fundamental investment thesis backing the Elite 7.

Company	Sector	Weight	Target P/E	Est. Yield	Investment Thesis
SQURPHARMA	Pharma	20%	8.5x	5.5%	The safest anchor in BD. Debt-free balance sheet with massive cash reserves. Best dividend coverage (~41% payout).
MARICO	FMCG	15%	13.5x	12.9%	Exceptional ROE and the highest cash yield in the portfolio. Provides extreme defensive stability against inflation.
LHBL	Cement	15%	12.0x	7.6%	Strongest earnings momentum (+33.7% YoY). Only fully integrated plant in BD provides a massive cost moat against peers.
BERGERPBL	Materials	15%	20.0x	3.8%	Near-monopoly category leader with immense pricing power. Premium valuation is consistently justified by brand strength.
RENATA	Pharma	15%	10.0x	1.1%	Aggressive reinvestment machine. Low payout ratio (~28%) drives long-term compounding and capital appreciation over yield.
ACMELAB	Pharma	10%	7.5x	4.6%	Deep value play. Cheaper multiple than Square with steady revenue growth (+12.5%) and a highly secure dividend yield.
OLYMPIC	FMCG	10%	16.0x	2.1%	Highly defensive staple. Predictable, stable demand ensures consistent low-double-digit earnings growth regardless of macro shocks.

A Shariah-compliant badge does not guarantee investment quality. Strict fundamentals are required.

GP & MJLBDLiquidated

Officially excluded from the CSE Shariah Index due to financial ratio breaches (interest income/debt thresholds). Must be permanently excluded.

WALTONHILWatchlist

Cut from the core portfolio. Recent -24% earnings contraction makes it too cyclically weak to hold as a core compounding pillar right now.

Beximco PharmaAvoid

Operationally strong, but severe regulatory overhang. Parent company liquidity crisis and BSEC-imposed board dispute mean it stays sidelined.

Islami BankAvoid

Largest Islamic bank by name, but latest data showed EPS growth collapse (-112%) and zero dividend. The name doesn't justify broken fundamentals.